Compare DexCom, Inc. (DXCM) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs NEOS S&P 500 High Income ETF — how do they compare? DexCom, Inc. trades at $89.2 (market cap $33.79B), while NEOS S&P 500 High Income ETF trades at $54.19. Which is the better fit depends on your goals.
| DXCM | SPYI | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $89.53 | $54.19 |
52-Week Low | $54.84 | $47.98 |
Enterprise Value | $33.24B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
